The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas.
The systemic treatment of soft tissue sarcomas is difficult due to the limited availability of active cytotoxic drugs. Combinations of cytotoxic drugs at standard doses do increase toxicity but do not improve response rates or survival. All combinations are limited by myelosuppression, mainly leukocytopenia. For at least two of the four active drugs (doxorubicin and ifosfamide) studies have shown a clear dose-response relationship. Recent studies have focused on increasing dose-intensity by increasing dosages or shortening treatment intervals, which is only possible by the use of hematological growth factors. This review will focus on the latter concept.
Rotterdam Cancer Institute, Daniel den Hoed Kliniek, The Netherlands.
G S
GS
Liem
J
J
Verweij
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D015337:Multicenter Studies as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012074:Remission Induction; D012509:Sarcoma / Q000150:complications / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins